Y-mAbs Therapeutics' Q2 revenue falls 14%

Reuters

2025/08/08

Y-mAbs <a href="https://laohu8.com/S/LENZ">Therapeutics</a>' <a href="https://laohu8.com/S/QTWO">Q2</a> revenue falls 14%

Overview

Y-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectations
SERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025
Co's acquisition agreement approved by Y-mAbs Board, tender offer by Aug. 19

Outlook

Y-mAbs did not provide further guidance due to pending acquisition
Company to be acquired by SERB Pharmaceuticals by Q4 2025

Result Drivers

U.S. REVENUE DECLINE - Driven by lower patient volume due to clinical study enrollments and increased competition
EX-U.S. REVENUE DROP - Attributed to absence of stocking orders from Western Europe and Eastern Asia
LICENSE REVENUE - $0.5 mln recognized from sales-based milestone achievements in Israel

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Product Revenue		$19.50 mln
Q2 EPS	Beat	-$0.07	-$0.27 (9 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $8.60, about 0.9% above its August 7 closing price of $8.52

Press Release: ID:nGNX47pmBL

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557523994"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557523994\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557523994?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557523994","market":"us","top_or_hot":-1,"title":"Y-mAbs Therapeutics' Q2 revenue falls 14%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Y-mAbs <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue falls 14%</title></head><body><p><span>Overview</span></p><ul><li><p>Y-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectations</p></li><li><p>SERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025</p></li><li><p>Co's acquisition agreement approved by Y-mAbs Board, tender offer by Aug. 19</p></li></ul><p><span>Outlook</span></p><ul><li><p>Y-mAbs did not provide further guidance due to pending acquisition</p></li><li><p>Company to be acquired by SERB Pharmaceuticals by Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>U.S. REVENUE DECLINE - Driven by lower patient volume due to clinical study enrollments and increased competition</p></li><li><p>EX-U.S. REVENUE DROP - Attributed to absence of stocking orders from Western Europe and Eastern Asia</p></li><li><p>LICENSE REVENUE - $0.5 mln recognized from sales-based milestone achievements in Israel</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Product Revenue</p></td><td></td><td><p>$19.50 mln</p></td><td></td></tr><tr><td><p>Q2 EPS</p></td><td><p>Beat</p></td><td><p>-$0.07</p></td><td><p>-$0.27 (9 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 10 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $8.60, about 0.9% above its August 7 closing price of $8.52</p></li></ul><p>Press Release: <span>ID:nGNX47pmBL</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Y-mAbs Therapeutics' Q2 revenue falls 14%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nY-mAbs Therapeutics' Q2 revenue falls 14%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-08 18:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Y-mAbs <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue falls 14%</title></head><body><p><span>Overview</span></p><ul><li><p>Y-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectations</p></li><li><p>SERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025</p></li><li><p>Co's acquisition agreement approved by Y-mAbs Board, tender offer by Aug. 19</p></li></ul><p><span>Outlook</span></p><ul><li><p>Y-mAbs did not provide further guidance due to pending acquisition</p></li><li><p>Company to be acquired by SERB Pharmaceuticals by Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>U.S. REVENUE DECLINE - Driven by lower patient volume due to clinical study enrollments and increased competition</p></li><li><p>EX-U.S. REVENUE DROP - Attributed to absence of stocking orders from Western Europe and Eastern Asia</p></li><li><p>LICENSE REVENUE - $0.5 mln recognized from sales-based milestone achievements in Israel</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Product Revenue</p></td><td></td><td><p>$19.50 mln</p></td><td></td></tr><tr><td><p>Q2 EPS</p></td><td><p>Beat</p></td><td><p>-$0.07</p></td><td><p>-$0.27 (9 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 10 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $8.60, about 0.9% above its August 7 closing price of $8.52</p></li></ul><p>Press Release: <span>ID:nGNX47pmBL</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"YMAB","symbol_name":"Y-mAbs Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nPLX540158:1","article_id":"2557523994","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557523994","pubTimestamp":1754649883,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Y-mAbs Therapeutics' Q2 revenue falls 14%OverviewY-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectationsSERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025Co's acqui","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"YMAB":"Y-mAbs Therapeutics, Inc."},"translate_title":"Y-mAbs Therapeutics第二季度收入下降14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YMAB":0.9},"content_text":"Y-mAbs Therapeutics' Q2 revenue falls 14%OverviewY-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectationsSERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025Co's acquisition agreement approved by Y-mAbs Board, tender offer by Aug. 19OutlookY-mAbs did not provide further guidance due to pending acquisitionCompany to be acquired by SERB Pharmaceuticals by Q4 2025Result DriversU.S. REVENUE DECLINE - Driven by lower patient volume due to clinical study enrollments and increased competitionEX-U.S. REVENUE DROP - Attributed to absence of stocking orders from Western Europe and Eastern AsiaLICENSE REVENUE - $0.5 mln recognized from sales-based milestone achievements in IsraelKey DetailsMetricBeat/MissActualConsensus EstimateQ2 Product Revenue$19.50 mlnQ2 EPSBeat-$0.07-$0.27 (9 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 10 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $8.60, about 0.9% above its August 7 closing price of $8.52Press Release: ID:nGNX47pmBL(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}